Core Viewpoint - Dongyangguang Changjiang Pharmaceutical (01558) reported a significant increase in revenue and profit for 2023, driven by enhanced brand recognition and strong performance across multiple product lines [1] Financial Performance - The company's revenue for 2023 was approximately RMB 6.295 billion, representing a year-on-year increase of 68.08% [1] - The profit attributable to equity holders and total comprehensive income was about RMB 1.993 billion, showing a remarkable year-on-year increase of 2501.23% [1] - Basic and diluted earnings per share were RMB 2.26 [1] Product Performance - The core product, Kewai (Oseltamivir Phosphate Capsules and Granules), along with other key products, contributed significantly to the overall revenue, with Kewai accounting for 87.53% of total revenue [1] - Sales of Kewai reached RMB 5.5095 billion, an increase of 78.15% compared to the previous year [1] - Other products such as Ertongshu (Bromfenac Tablets), Oumeining (Telmisartan Tablets), Linluoxing (Moxifloxacin Hydrochloride Tablets), and Olmesartan Medoxomil Tablets contributed 1.51%, 1.24%, 0.71%, and 0.66% to total revenue, respectively [1] Market Dynamics - The increase in Kewai's sales was primarily attributed to the normalization of domestic personnel movement and social activities in 2023, leading to a recovery in foot traffic at medical institutions, diagnostic activities, and prescription volumes [1]
东阳光长江药业(01558)公布2023年业绩 归母净利约19.93亿元 同比增加2501.23%